NICE recommends flu drug for “at risk” patientsBMJ 2000; 321 doi: https://doi.org/10.1136/bmj.321.7272.1305/a (Published 25 November 2000) Cite this as: BMJ 2000;321:1305
- Jason O'Neale Roach
The National Institute for Clinical Excellence (NICE) recommended this week that zanamivir (Relenza) should be used to treat “at risk” adults when influenza is circulating in the community and if they present within 36 hours of developing symptoms. The institute defines such patients as those with chronic respiratory disease, significant cardiovascular disease, diabetes, or a compromised immune system, and those …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial